Primary tumor genotype is an important determinant in identification of lung cancer propagating cells - PubMed (original) (raw)

Primary tumor genotype is an important determinant in identification of lung cancer propagating cells

Stephen J Curtis et al. Cell Stem Cell. 2010.

Abstract

Successful cancer therapy requires the elimination or incapacitation of all tumor cells capable of regenerating a tumor. Therapeutic advances therefore necessitate the characterization of the cells that are able to propagate a tumor in vivo. We show an important link between tumor genotype and isolation of tumor-propagating cells (TPCs). Three mouse models of the most common form of human lung cancer each had TPCs with a unique cell-surface phenotype. The cell-surface marker Sca1 did not enrich for TPCs in tumors initiated with oncogenic Kras, and only Sca1-negative cells propagated EGFR mutant tumors. In contrast, Sca1-positive cells were enriched for tumor-propagating activity in Kras tumors with p53 deficiency. Primary tumors that differ in genotype at just one locus can therefore have tumor-propagating cell populations with distinct markers. Our studies show that the genotype of tumor samples must be considered in studies to identify, characterize, and target tumor-propagating cells.

Copyright (c) 2010 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Orthotopic transplantation of Kras and Kras;p53-flox tumor cells recapitulates the primary tumor phenotype. (A) Cartoon of the transplantation scheme used to assay lung tumor-propagating cells (TPCs) through serial transplantation. (B) H&E staining of primary (left) and secondary (right) Kras lung adenocarcinomas showing similar pathological grade, nuclear features, and general tumor architecture. (C) H&E staining of primary (left) and secondary (right) Kras;p53-flox lung tumors showing similar histopathological characteristics of advanced adenocarcinoma, including pleomorphic nuclei and rare giant cells. All images, 200× magnification. Scale bar = 100μM.

Figure 2

Figure 2

Sca1 + cells from Kras;p53-flox tumors are lung tumor-propagating cells. (A) Representative FACS analysis of Kras;p53-flox tumor cells used for transplantation (top). Limiting dilution transplantation of the sorted cells indicated that the Sca1 + population was significantly enriched for TPCs (table). (B) Sca1- cell transplants yielded smaller, more diffuse lesions (left), whereas Sca1 + cell transplants yielded secondary tumors that recapitulated the histopathology of primary Kras;p53-flox tumors (right, compare to Figure 1C). (C) Immunofluorescence (IF) staining with antisera raised against SP-C (red), CCSP (green), and counterstain DAPI (blue) showed that primary Kras;p53-flox lung adenocarcinomas (left) are mainly composed of SP-C+ cells, a pattern recapitulated in secondary tumors from Sca1 + cell transplants (right). (D) Serial transplantation of secondary tumor cell populations revealed a lack of tumor formation from Sca1 - cells (left), in contrast to tertiary tumor development from Sca1 + cells (right). All images, 200× magnification. Scale bar = 100μM. See also Figure S1 and Table S1 for additional data.

Figure 3

Figure 3

The Sca1 + and Sca1- populations from Kras lung tumors are equally capable of propagating tumors. (A) Representative FACS analysis of Kras tumors showing a pattern of Sca1 staining similar to Kras;p53-flox tumors (top, compare to Figure 2A). Limiting dilution transplantation indicated that Sca1+ and Sca1- Kras tumor cells are identical in tumor-propagating potential (table). (B) Secondary tumors from Sca1- (left) and Sca1+ (right) Kras tumor cell transplants displayed similar pathological features. (C) IF analysis of secondary tumors (as in Figure 2) revealed similar SP-C and CCSP marker status in secondary tumors from Sca1- cells (left) and Sca1+ cells (right). (D) Both Sca1- Kras tumor cells (left) and Sca1+ tumor cells (right) were capable of serial transplantation to form tertiary tumors. All images, 200× magnification. Scale bar = 100μM. See also Figure S2 and Table S2 for additional data.

Comment in

Similar articles

Cited by

References

    1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:3983–3988. - PMC - PubMed
    1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature medicine. 1997;3:730–737. - PubMed
    1. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE. 2008;3:e2637. - PMC - PubMed
    1. Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G, Gurney A, Lewicki J, Clarke MF. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells. 2008;26:364–371. - PubMed
    1. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–1075. - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources